Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML
Shots:
- The P-III QuANTUM-First trial evaluates quizartinib vs placebo in combination with standard induction and consolidation CT & continued with quizartinib as monothx. in a ratio (1:1) in 539 patients aged 18-75yrs. with newly diagnosed FLT3-ITD positive AML at ~ 200 study sites globally including in Asia, EU, America & Oceania
- The results showed an improvement in OS over standard treatment alone. The safety of quizartinib was manageable & consistent with the known safety profile. The results will be shared with authorities globally
- Quizartinib is an oral, highly potent & selective type II FLT3 inhibitor & is approved for use in Japan under the brand name Vanflyta to treat r/r FLT3-ITD AM
| Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com